CI
REGN icon

Capital International’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital International’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.52M Buy
13,665
+55
+0.4% +$37.4K 0.28% 86
2026
Q1 		$10.5M Hold
13,610
– – 0.39% 70
2025
Q4 		$10.5M Sell
13,610
-14,302
-51% -$9.71M 0.37% 71
2025
Q3 		$15.7M Sell
27,912
-5,999
-18% -$3.39M 0.57% 51
2025
Q2 		$17.8M Sell
33,911
-9,241
-21% -$5.16M 0.68% 46
2025
Q1 		$27.4M Buy
43,152
+2,184
+5% +$1.5M 1.19% 23
2024
Q4 		$29.2M Buy
40,968
+5,197
+15% +$4.36M 1.19% 20
2024
Q3 		$37.6M Buy
35,771
+997
+3% +$1.11M 1.62% 13
2024
Q2 		$36.5M Buy
34,774
+3,741
+12% +$3.63M 1.69% 13
2024
Q1 		$29.9M Buy
31,033
+7,007
+29% +$6.66M 1.43% 16
2023
Q4 		$21.1M Buy
24,026
+464
+2% +$382K 1.08% 20
2023
Q3 		$19.4M Sell
23,562
-4,806
-17% -$3.78M 1.12% 18
2023
Q2 		$20.4M Sell
28,368
-2,919
-9% -$2.25M 1.14% 19
2023
Q1 		$25.7M Sell
31,287
-604
-2% -$456K 1.54% 10
2022
Q4 		$23M Sell
31,891
-598
-2% -$441K 1.59% 10
2022
Q3 		$22.4M Buy
32,489
+3,446
+12% +$2.17M 1.56% 10
2022
Q2 		$17.2M Buy
29,043
+1,387
+5% +$902K 1.29% 14
2022
Q1 		$19.3M Buy
27,656
+3,171
+13% +$2.01M 1.1% 18
2021
Q4 		$15.5M Buy
24,485
+104
+0.4% +$63.9K 0.79% 33
2021
Q3 		$14.8M Sell
24,381
-288
-1% -$179K 0.8% 31
2021
Q2 		$13.8M Sell
24,669
-1,139
-4% -$577K 0.76% 36
2021
Q1 		$12.2M Sell
25,808
-2,616
-9% -$1.27M 0.74% 33
2020
Q4 		$13.7M Buy
28,424
+319
+1% +$172K 0.8% 30
2020
Q3 		$15.7M Buy
28,105
+4,803
+21% +$2.91M 1.07% 25
2020
Q2 		$14.5M Sell
23,302
-264
-1% -$150K 1.36% 21
2020
Q1 		$11.5M Buy
+23,566
New +$9.72M 1.29% 21
2018
Q3 		– Sell
-8,223
Closed -$2.84M – 162
2018
Q2 		$2.84M Sell
8,223
-99
-1% -$31K 0.5% 66
2018
Q1 		$2.87M Buy
+8,322
New +$2.89M 0.51% 64

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital International's REGN Position: Q2 2026 in Review

Capital International increased its Regeneron Pharmaceuticals (REGN) stake by 0.4% in Q2 2026, buying an estimated $37.4K and bringing the position to 13,665 shares worth $8.52M. The position accounts for 0.28% of the portfolio, ranked #86.

Capital International first reported a position in REGN in Q1 2018 and has held it in 28 quarters since. The position peaked at $37.6M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital International held 13,665 shares of Regeneron Pharmaceuticals worth $8.52M as of Q2 2026.
  • Capital International bought 55 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $37.4K.
  • Regeneron Pharmaceuticals made up 0.28% of Capital International's portfolio in Q2 2026, its #86 holding.
  • Capital International first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • Capital International's Regeneron Pharmaceuticals position peaked at $37.6M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital International's 13F filing for Q2 2026, filed 12 Aug 2026.